Immune reconstitution and survival, following hematopoietic stem cell transplantation in Omani patients with inborn errors of immunity.
Clin Immunol
; 264: 110263, 2024 Jul.
Article
en En
| MEDLINE
| ID: mdl-38795901
ABSTRACT
BACKGROUND:
Hematopoietic stem cell transplantation (HSCT) is a curative treatment for certain inborn errors of immunity.METHODS:
A 17-year retrospective cohort study was conducted on 40 immunodeficient patients who underwent HSCT.RESULTS:
The median age at transplant was 11.0 months (4.6-61.0). Donors were primarily matched sibling donors (60%). 90% and 85% of patients received conditioning and graft-versus-host disease (GVHD) prophylaxis, respectively. The mean donor chimerism at the last follow-up was 88.6% ± 17.9% (40-100). Median serum immunoglobulin (Ig) G level, CD4+ T-cell count, and CD19+ B-cell count were 11.7 g/L (9.2-13.6), 0.9 × 109/L 0.6-1.2), and 0.5 × 109/L (0.2-0.7), respectively. 29 patients (72.5%) received intravenous immunoglobulins (IVIG) therapy, with a median duration of 10.0 months (4.0-14.0). The median post-transplant follow-up was 6.5 years (IQR1.4-11.5). The 10-year overall probability of survival is 84.3%.CONCLUSION:
Monitoring IRC is important in ensuring adequate disease-free survival.Palabras clave
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Trasplante de Células Madre Hematopoyéticas
/
Reconstitución Inmune
/
Enfermedad Injerto contra Huésped
Límite:
Child, preschool
/
Female
/
Humans
/
Infant
/
Male
País/Región como asunto:
Asia
Idioma:
En
Revista:
Clin Immunol
Asunto de la revista:
ALERGIA E IMUNOLOGIA
Año:
2024
Tipo del documento:
Article